In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans
Authors:
- 1 January 2003
- journal article
- clinical trial
- Published by Taylor & Francis in Xenobiotica
- Vol. 33 (4) , 399-414
Abstract
1. The plasma concentration-time profile of the 14 C-labelled endothelin receptor antagonist tezosentan in healthy male volunteers after a 1-h infusion at 100 mg h − 1 followed a biphasic decline with half-lives of 3-5 min for the initial disposition phase and approximately 4 h for the terminal phase. 2. Tezosentan was predominantly excreted unchanged into faeces, whereas less than 5% of the dose was excreted as unchanged drug in urine. Two isomeric, hydroxylated metabolites (M1, M2) were detected in faeces representing 2-5% of the total radioactivity. 3. In vitro, with human liver microsomes and primary hepatocytes, tezosentan was metabolized at very low rates. Upon prolonged incubation with human hepatocytes for 24 h, formation of the hydroxylated metabolite M1 and a glucuronic acid conjugate, M3, was observed. 4. No relevant inhibition of the human cytochrome P450 (CYP) forms, CYP1A2, 2C9, 2C19, 2D6 and 3A4, was observed in vitro at tezosentan concentrations largely exceeding those observed in clinical trials. 5. In human blood, tezosentan was highly bound to plasma proteins, mainly albumin, and hardly penetrated into red blood cells.Keywords
This publication has 14 references indexed in Scilit:
- Entry-Into-Humans Study with Tezosentan, an Intravenous Dual Endothelin Receptor AntagonistJournal of Cardiovascular Pharmacology, 2002
- Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjectsBritish Journal of Clinical Pharmacology, 2002
- Implications of Cytochrome P450 2C9 Polymorphism on Warfarin Metabolism and DosingPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†Drug Metabolism Reviews, 2001
- Fluorometric High‐Throughput Screening for Inhibitors of Cytochrome P450Annals of the New York Academy of Sciences, 2000
- Fluorometric screening for metabolism-based drug–drug interactionsJournal of Pharmacological and Toxicological Methods, 2000
- Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatmentPharmacogenomics, 2000
- Endothelin in renal pathophysiology: From experimental to therapeutic applicationKidney International, 1996
- Fragmentation of Bosentan ® (Ro 47-0203) in ionspray mass spectrometry after collision-induced dissociation at low energy: a case of radical fragmentation of an even-electron ionJournal of Mass Spectrometry, 1996
- Microbial succession and intestinal enzyme activities in the developing ratJournal of Applied Bacteriology, 1994